ReviewMolecular biomedicine2026
Neuroimmune interactions: from molecular mechanisms to therapeutic targets.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neuroimmune interactions reveal that the central nervous system (CNS) is dynamically integrated with peripheral immunity. This bidirectional communication is mediated by microglia, astrocytes, peripheral immune cells, and the neurovascular unit through cytokines, chemokines, complement proteins, neurotransmitters, and neuropeptides. At the molecular level, pattern-recognition receptors, including Toll-like receptors and nucleotide-binding oligomerization domain-like receptors, activate NF-κB, MAPK, and JAK-STAT signaling. These pathways regulate cytokine production, oxidative stress, cellular metabolism, and glial phenotypes. NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome activation induces caspase-1-dependent maturation of IL-1β and IL-18 and promotes pyroptosis, thereby amplifying neuroinflammation. Complement C1q/C3-CR3 signaling mediates synaptic pruning, whereas C-C motif chemokine ligand 2 (CCL2)-CCR2 signaling promotes leukocyte recruitment and microglial activation. Cytokines and matrix metalloproteinases disrupt endothelial tight junctions and compromise blood-brain barrier integrity. In addition, calcitonin gene-related peptide (CGRP) and substance P activate neuropeptide receptors to drive neurogenic inflammation. Together, these molecular circuits regulate glial activation, immune-cell trafficking, synaptic remodeling, neuronal excitability, vascular function, and cell survival. Their dysregulation contributes to neurodegenerative, neuroinflammatory, psychiatric, neurodevelopmental, and peripheral diseases through the blood-brain barrier, gut-brain axis, and vagus nerve. This Review summarizes how molecular neuroimmune mechanisms drive disease initiation, progression, and heterogeneity, and discusses emerging therapies targeting inflammasomes, complement, chemokine receptors, neuropeptide signaling, and microbiota to advance biomarker-guided, personalized neuroimmune medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.